The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations
With the current crisis related to the emergence of carbapenem-resistant Gram-negative bacteria (CR-GNB), classical treatment approaches with so-called "old-fashion antibiotics" are generally unsatisfactory. Newly approved β-lactam/β-lactamase inhibitors (BLBLIs) should be considered as th...
Enregistré dans:
Auteurs principaux: | Abdullah Tarık Aslan (Auteur), Murat Akova (Auteur) |
---|---|
Format: | Livre |
Publié: |
MDPI AG,
2022-02-01T00:00:00Z.
|
Sujets: | |
Accès en ligne: | Connect to this object online. |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors
par: Giacomo Luci, et autres
Publié: (2021) -
Revisiting the Checkerboard to Inform Development of β-Lactam/β-Lactamase Inhibitor Combinations
par: Darren J. Bentley
Publié: (2024) -
Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance
par: Anna Duda-Madej, et autres
Publié: (2023) -
β-Lactam Antibiotics and β-Lactamase Enzymes Inhibitors, Part 2: Our Limited Resources
par: Silvana Alfei, et autres
Publié: (2022) -
β-lactam susceptibility in extended-spectrum β-lactamase-producing isolates
par: Gopal Nandlal Agrawal, et autres
Publié: (2017)